- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05306509
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE)
March 17, 2026 updated by: Children's Hospital of Fudan University
Facilitating Early Integration of Palliative Care in Pediatric Oncology: Development and Implementation of a Nurse-initiated Conversation Program for Pediatric Cancer Patients and Their Families
This study aims to develop and implement a pediatric palliative care (PPC) program.
It is an open-label, randomized trial (2:1 randomization) in pediatric oncology department of Children's Hospital of Fudan University.
The intervention group will receive Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE).
The control group will receive routine PPC (will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment).
The intervention will take 6 months.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Early integration of PPC, endorsed by a number of international societies, is well supported by evidence on providing multi-layer relief in children and their families over the course of any life-threatening illness.
This study will leverage oncology nurses' role, culturally adapt the well-recognized St. Jude Children's Individualized Care Planning and Coordination (ICPC) Model to develop and evaluate a nurse-initiated conversation program to facilitate early integration of palliative care in pediatric oncology care.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lei Cheng, PhD
- Phone Number: +8602164161784
- Email: chenglei@fudan.edu.cn
Study Contact Backup
- Name: Xiaowen Zhai, MD
- Phone Number: +8602164931123
- Email: zhaixiaowendy@163.com
Study Locations
-
-
Minhang
-
Shanghai, Minhang, China, 201102
- Recruiting
- Hemotology/Oncology Unit and Surgical Oncology Unit of Children's Hospital of Fudan University
-
Contact:
- Hongsheng Wang, MD
- Phone Number: 8613916453373
- Email: honswang@hotmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Children within eight weeks of initial oncologic diagnosis or within eight weeks of relapse/recurrent disease diagnosis
- Children speaking Chinese
- Children's family caregivers accompanying the child in the hospital (only one family member is eligible to take this role under current hospital policy)
- Children's family caregivers speaking Chinese
- Health care providers who are taking care of the eligible children, including but not limited to physicians, nurses, and social workers
Exclusion Criteria:
- Children who, in the opinion of their physician, are not capable mentally or verbally of participating in the survey or interview
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Nurse-initiated conversations for early integration of palliative care (NiCE)
Participants will receive nurse-initiated conversations facilitating early integration of palliative care in pediatric oncology.
|
Participants will receive an initial conversation led by a trained senior nurse within eight weeks after initial oncologic diagnosis or relapse/recurrent disease diagnosis, with an introduction to the intervention and learning about the goals, values, hopes, and fears of each patient and family.
The PPC team will then follow each patient by ongoing regular conversations (related to the child and family's conditions) led by the same nurse, every 4 weeks for six months, when symptom assessment and management, goal-directed supportive care, team collaboration, and care coordination will be delivered according to the family's needs.
Increased PPC involvement, end-of-life care and bereavement care will be involved when necessary.
If a participant feels any discomfort or distress during the intervention, a break will be taken until they feel better.
If not, the central contact person will come and discussion about the participant's feeling and wiliness to continue the intervention.
|
|
Other: Routine PPC
Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
|
Participants will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Scores of children's quality of life
Time Frame: Measured every three months over six months.
|
Scores of children's quality of life will be measured by Peds Quality of Life TM4.0 scale.
It encompasses four subscales: physical, emotional, social and school functioning.
It asks how much of a problem each item has been during the past month.
It comprised of parallel child self-report and parent proxy-report formats.
Child self-report includes ages 5-7 years (young child), ages 8-12 years (child), and ages 13-18 years (adolescent).
All items use a five-point Likert response set range from 'never' to 'almost always'.
Items are reverse-scored and linear-early transformed to a scale of 0 to 100 (0 = 100, 1= 75, 2= 50, 3= 25, 4=0), so that higher scores indicate a better quality of life.
It is a repeated measurement, will be measured at baseline, three months and six months, for three times.
|
Measured every three months over six months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events
Time Frame: Measured every four weeks over six months.
|
Incidence of adverse events (AEs) will be measured by the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PED-PRO-CTCAE).
This study will measure the incidence of 15 core AEs (abdominal pain, anorexia, nausea, vomiting, constipation, diarrhea, cough, pain, headache, neuropathy, mucositis, anxiety, depression, fatigue, insomnia), as perceived and reported by children 7 to 18 years of age or parent proxy (0-18 years), using a 7-day reference period with 4 response options per item.
Presence of each of the 15 AEs will be measured as a dichotomous variable of the AE symptom (1-if any of the AEs happens; 0-none AEs).
It is a repeated measurement, will be measured at baseline and every four weeks, for seven times.
|
Measured every four weeks over six months.
|
|
Scores of children's mobility
Time Frame: Measured every three months over six months.
|
Scores of children's mobility will be measured by Pediatric patient-reported outcomes measurement information system (Pediatric PROMIS) Short Form v2.0 - Mobility 8a.
It can be reported by children 7 to 18 years of age or parent proxy (0-18 years) in relation to the past 7 days and in terms of a five-point response option range from 'never' to 'almost always' in most measures.
Higher scores mean more of the measured symptom being experienced.
The short form measure has 8 items and receives a T-score with a mean of 50 and a standard deviation of 10 based on the original reference sample.
It is a repeated measurement, will be measured at baseline and every four weeks, for seven times.
|
Measured every three months over six months.
|
|
Scores of children's family caregivers' care burden
Time Frame: Measured every three months over six months.
|
Scores of children's family caregivers' care burden will be measured by Zarit Burden Inventory, by the family caregivers' self-reports.
It is a 22-item, 5-point scale ranging from never (0) to always (4).
A higher score indicates higher care burden.
It is a repeated measurement, will be measured at baseline, three months and six months, for three times.
|
Measured every three months over six months.
|
|
Scores of children's family caregivers' anxiety
Time Frame: Measured every three months over six months.
|
Scores of children's family caregivers' anxiety will be measured by Zung's Self-Rating Anxiety Scale (SAS), by the family caregivers' self-reports.
It is a 20-item, 4-point scale ranging from never (1) to often (4).
The total score of 1.25 is the final standard score.
A higher score indicates a severer anxiety symptom.
It is a repeated measurement, will be measured at baseline, three months and six months, for three times.
|
Measured every three months over six months.
|
|
Scores of children's family caregivers' depression
Time Frame: Measured every three months over six months.
|
Scores of children's family caregivers' depression will be measured by Zung's Self-Rating Depression Scale (SDS) , by the family caregivers' self-reports.
It is a 20-item, 4-point scale ranging from never (1) to often (4).
The total score of 1.25 is the final standard score.
A higher score indicates severer depressive symptoms.
It is a repeated measurement, will be measured at baseline, three months and six months, for three times.
|
Measured every three months over six months.
|
|
Acceptability of the NiCE intervention
Time Frame: At the sixth month of the study.
|
Acceptability will be captured by interviews of family caregivers and healthcare workers about whether the content of this intervention is acceptable.
Each participant will be asked about the same question: "Please tell me whether you think this intervention is acceptable?
Please tell me more about your answer to this question".
Acceptability will be defined when the participant clearly answered "yes".
|
At the sixth month of the study.
|
|
Appropriateness of the NiCE intervention
Time Frame: At the sixth month of the study.
|
Appropriateness will be assessed by interviews of family caregivers and healthcare workers of the intervention arm whether the content of this intervention is appropriate.
Each participant will be asked about the same question: "Please tell me whether you think this intervention is appropriate?
Please tell me more about your answer to this question".
Appropriateness will be defined when the participant clearly answered "yes".
|
At the sixth month of the study.
|
|
Feasibility of the NiCE intervention
Time Frame: At the sixth month of the study.
|
Feasibility will be assessed by the number of nurses led conversations that actually occurred during the 6-month period.
|
At the sixth month of the study.
|
|
Barriers and facilitators
Time Frame: At the sixth month of the study.
|
Barriers and facilitators will be assessed by interviews of family caregivers and healthcare workers of the intervention arm.
Each participant will be asked about the same two questions: (1) "Please tell me whether you think there is any barrier during the intervention?
Please tell me more about your answer to this question".
(2) "Please tell me whether you think there is any facilitators during the intervention?
Please tell me more about your answer to this question".
|
At the sixth month of the study.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xiaowen Zhai, MD, Children's Hospital of Fudan University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Haun MW, Estel S, Rucker G, Friederich HC, Villalobos M, Thomas M, Hartmann M. Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev. 2017 Jun 12;6(6):CD011129. doi: 10.1002/14651858.CD011129.pub2.
- Schmidt P, Otto M, Hechler T, Metzing S, Wolfe J, Zernikow B. Did increased availability of pediatric palliative care lead to improved palliative care outcomes in children with cancer? J Palliat Med. 2013 Sep;16(9):1034-9. doi: 10.1089/jpm.2013.0014. Epub 2013 Jul 31.
- Mahmood LA, Casey D, Dolan JG, Dozier AM, Korones DN. Feasibility of Early Palliative Care Consultation for Children With High-Risk Malignancies. Pediatr Blood Cancer. 2016 Aug;63(8):1419-22. doi: 10.1002/pbc.26024. Epub 2016 May 3.
- Lafond DA, Kelly KP, Hinds PS, Sill A, Michael M. Establishing Feasibility of Early Palliative Care Consultation in Pediatric Hematopoietic Stem Cell Transplantation. J Pediatr Oncol Nurs. 2015 Sep-Oct;32(5):265-77. doi: 10.1177/1043454214563411. Epub 2015 Jan 23.
- Levine DR, Johnson LM, Snyder A, Wiser RK, Gibson D, Kane JR, Baker JN. Integrating Palliative Care in Pediatric Oncology: Evidence for an Evolving Paradigm for Comprehensive Cancer Care. J Natl Compr Canc Netw. 2016 Jun;14(6):741-8. doi: 10.6004/jnccn.2016.0076.
- Baker JN, Hinds PS, Spunt SL, Barfield RC, Allen C, Powell BC, Anderson LH, Kane JR. Integration of palliative care practices into the ongoing care of children with cancer: individualized care planning and coordination. Pediatr Clin North Am. 2008 Feb;55(1):223-50, xii. doi: 10.1016/j.pcl.2007.10.011.
- Snaman J, McCarthy S, Wiener L, Wolfe J. Pediatric Palliative Care in Oncology. J Clin Oncol. 2020 Mar 20;38(9):954-962. doi: 10.1200/JCO.18.02331. Epub 2020 Feb 5.
- Neuburg L. Early Initiation of Pediatric Palliative Care. J Pediatr Health Care. 2021 Jan-Feb;35(1):114-119. doi: 10.1016/j.pedhc.2020.05.006. Epub 2020 Jul 10.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2022
Primary Completion (Estimated)
May 31, 2026
Study Completion (Estimated)
July 31, 2026
Study Registration Dates
First Submitted
March 20, 2022
First Submitted That Met QC Criteria
March 29, 2022
First Posted (Actual)
April 1, 2022
Study Record Updates
Last Update Posted (Actual)
March 19, 2026
Last Update Submitted That Met QC Criteria
March 17, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NiCE_21_427
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Avelos Therapeutics Inc.RecruitingSolid Tumor | Solid Tumor Cancer | Solid Tumor, Adult | Solid Tumor, Unspecified, Adult | Tumor, Solid | Solid Tumor in Advanced Stage | Solid Tumors Refractory to Standard TherapyKorea, Republic of
-
Monopar TherapeuticsAvailableCancer | Solid Tumor | Solid Tumor Cancer | Oncology | uPAR-positive Solid Tumor | Urokinase Plasminogen Activator Receptor-positive Solid TumorUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Australia, Taiwan, United States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
Clinical Trials on NiCE
-
Neuronix LtdAssaf-Harofeh Medical CenterCompletedAlzheimer Disease | Mild to ModerateIsrael
-
University of LeedsActive, not recruitingCardiovascular Diseases | Pulmonary Disease | Metabolic Disease | Renal DiseaseUnited Kingdom
-
University of ChicagoCenters for Disease Control and Prevention; Howard Brown Health Center; Chicago...Completed
-
Centre Hospitalier Universitaire de NiceCompleted
-
Neuronix LtdChungnam National University Hospital; company: K The PowerCompleted
-
Neuronix LtdCompletedAlzheimer's DiseaseUnited States, Israel
-
Henry Ford Health SystemCompletedHidradenitis SuppurativaUnited States
-
Neuronix LtdTerminated
-
Fundació Sant Joan de DéuCompletedRefractory Neuroblastoma | Soft Tissue CancerSpain
-
Tianjin Chest HospitalRecruitingChronic Coronary SyndromeChina